pegylated teduglutide (QPG-1030) / QuiaPEG Pharma - LARVOL DELTA

QuiaPEG conducts issue for development and partnership (BioStock) - "The drug delivery company QuiaPEG Pharmaceuticals develops improved drugs against diabetes, obesity and short bowel syndrome. The company has a scalable platform, preclinical proof-of-concept in two pharmaceutical projects and plans for out-licensing and partnerships. QuiaPEG is now carrying out a fully guaranteed rights issue of SEK 20.5 million to continue to drive project and business development with the aim of entering into license/partnership agreements and settling loans....QuiaPEG has achieved preclinical proof-of-concept in two drug projects, QPG-1030 and QPG-1029....The candidate QPG-1030 is aimed at the orphan drug indication short bowel syndrome, and is based on teduglutide, the active substance in Takeda's Gattex/Revestive . Preclinical results for QPG-1030 indicate that weekly administration is within reach instead of the current daily dosing as is the case with Gattex."

Licensing / partnership • Orphan drug • Preclinical • Short Bowel Syndrome